TrialJournal for immunotherapy of cancer2021

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma.

Sapna P Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.